ArticleInternational forum of allergy & rhinology2026
Leptin May Promote Eosinophilic CRSwNP Progression by Enhancing Eosinophil Chemotaxis and Angiogenesis Under a Type 2 Inflammatory Milieu.
Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChronic rhinosinusitis with nasal polyp (CRSwNP) is a heterogeneous Type 2 inflammatory disease characterized by enhanced eosinophilic infiltration. Both innate and adaptive immunity are involved in the onset and progression of CRSwNP. Increased serum leptin levels are associated with various allergic conditions; however, the biological role of leptin in allergic immune cells requires further investigation.
objectiveTo investigate the effects of leptin on immune cells, including eosinophils, basophils, and mast cells, in CRSwNP.
methodsLeptin was used to stimulate eosinophils and eosinophilic cell lines, followed by analyses of gene expression, migration, and angiogenic capacity. Immunometabolic profile of CRSwNP, serum leptin, and galectin-10 levels were analyzed in conjunction with the gene expression profiles of nasal polyps. Furthermore, the biological effects of leptin on eosinophils were assessed using RNA sequencing and functional analyses, including a transwell migration assay and an angiogenesis assay via co-culture with human umbilical vein endothelial cells (HUVEC).
resultsIncreased serum leptin and galectin-10 levels were associated with Type 2 inflammatory markers and correlated with CRSwNP severity. RNA sequencing revealed upregulation of chemokine ligands in eosinophilic cell lines. Leptin induced plasminogen activator inhibitor 1 (PAI-1) expression in eosinophils but not in basophils or neutrophils. Leptin pretreatment substantially enhanced migration toward both C-C motif chemokine ligand (CCL) 11 and CCL26 in eosinophilic cell lines. The leptin-primed eosinophilic cell line promoted angiogenesis, as demonstrated in co-culture with HUVECs.
conclusionLeptin promotes eosinophil migration and angiogenesis, potentially via chemokine ligands and PAI-1 induction, and may promote CRSwNP progression under a Type 2 inflammatory milieu.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.